Summary
Chylothorax is an unusual cause of pleural effusion, typically caused by trauma or malignancy. Waldenstrom's macroglobulinaemia (WM) is a clinicopathological entity demonstrating lymphoplasmacytic lymphoma in the bone marrow with an IgM monoclonal gammopathy in the blood. Recurrent chylous effusions are often resistant to conservative treatment and may require surgical intervention. We present a unique case of a 50-yearold woman with recurrent chylothorax secondary to WM that completely resolved with ibrutinib therapy. To our knowledge, this is the eighth such case reported in literature and the first case of successful resolution of chylothorax with monoclonal antibody therapy.
Background
Pleural effusion is a common clinical problem, with estimated 1-1.5 million new cases in the USA each year. 1 It is defined as an excess of fluid in the pleural cavity and is a consequence of imbalance of pleural fluid production, absorption or both. Chylothorax is a rare cause of pleural effusion that results from thoracic duct damage with chyle leakage from the lymphatic system into the pleural space. Chylothoraces contain a high concentration of triglycerides in the form of chylomicrons, lymphocytes and immunoglobulins.
Iatrogenic injury from thoracic surgery is the most common traumatic cause, while non-traumatic causes include various aetiologies such as malignancy, sarcoidosis, amyloidosis, congenital duct abnormalities and diseases of the lymph vessels such as yellow nail syndrome and lymphangioleiomyomatosis. [2] [3] [4] Clinically, dyspnoea, chest pain and cough are the most common symptoms of chylothorax. Malnutrition from loss of protein and immunosuppression from loss of immunoglobulins into pleural space might lead to weight loss and infections. 5 Imaging typically shows pleural effusion that is most often right-sided due to the anatomy of thoracic duct. Thoracic duct crosses from the right to left posterior mediastinum at level of T5; thus, damage to the duct above T5 typically leads to leftsided effusion, whereas damage below leads to a right-sided effusion. 6 Pleural fluid appearance might be the first clue to diagnosing chylothorax. The appearance of fluid from a chylothorax is typically milky; however, it can be serous or sanguineous. 7 Cholesterol pleural effusion and empyema might appear similar. Supernatant of the pleural fluid from a chylothorax typically fails to clear after centrifugation, whereas empyema fluid clears. 8 Pleural fluid triglyceride level over 110 mg/dL is diagnostic of chylothorax; however, 15% of chylothoraces can have lower triglyceride levels. 8 Lipoprotein electrophoresis of the pleural fluid showing chylomicrons is confirmatory in uncertain cases. 9 Cholesterol is usually <200 mg/dL; higher levels are typical for cholesterol effusion. 10 Treatment of chylothorax consists of treatment of the underlying aetiology, a low-fat diet and drainage. Octreotide/somatostatin and etilefrine therapy might be highly efficacious in conservative management. Recurrent chylothorax often requires surgical treatment such as thoracic duct ligation, talc pleurodesis or pleuroperitoneal shunt placement. 11 Lymphatic interventions have recently emerged as a new frontier for interventional radiologists. 12 Waldenstrom's macroglobulinaemia (WM) is a rare disorder with an annual incidence of approximately three per million people. 13 14 It is characterised by the presence of lymphoplasmacytic lymphoma in the bone marrow with an IgM monoclonal gammopathy in the blood. Bone marrow examination in WM should demonstrate at least 10% of infiltration by small lymphocytes with lymphoplasmacytic features or lymphoplasmacytic lymphoma. The other requisite pathological feature of WM is the hypersecretion of a monoclonal IgM paraprotein. 15 16 Symptoms of WM are related to infiltration of haematopoietic tissues or effects of monoclonal IgM in the blood. IgM paraprotein can cause various symptoms resulting from systemic amyloidosis, paraprotein depositions in the organs, cryoglobulinaemia, peripheral neuropathy and hyperviscosity syndrome. Hyperviscosity can cause neurological symptoms such as blurring of vision, headache, vertigo, confusion, stroke or coma. About 20% to 25% of patients with WM develop peripheral neuropathy from sensory demyelination related to antimyelin-associated glycoprotein antibody.
Rituximab is commonly used as first-line treatment of symptomatic patients; however, novel immunotherapies such as recently approved tyrosine kinase inhibitor ibrutinib are emerging. 15 We present a unique case of recurrent chylothorax secondary to WM. The pathogenesis of chylothorax in our case is believed to be compression of thoracic duct by an enlarged mediastinal lymph node. To our knowledge, this is the seventh such case reported in literature and the first case of successful resolution of chylothorax with monoclonal antibody therapy. A 50-year-old Caucasian woman presented to the emergency department with right-sided pleuritic chest that began 1 day prior. She had noted progressive dyspnoea for the past month. She denied any other associated symptoms such as fever, weight loss, fatigue, lymphadenopathy, nausea or vomiting. Her medical history was significant for WM, discovered 3 years ago. She was found to have low-grade B-cell non-Hodgkin's lymphoma, most consistent with lymphoplasmacytic lymphoma, with 20%-30% bone marrow involvement and elevated serum IgM kappa levels. She was asymptomatic during these past 3 years and was observed without any specific treatment.
In the emergency department, she was found to be normotensive and did not have signs of respiratory failure. Physical examination revealed palpable adenopathy in bilateral anterior cervical as well as the left supraclavicular region. Her lung examination revealed absent breath sounds in the right lower lobe. Cardiovascular and abdominal examinations were unremarkable.
inveSTigaTionS
Initial laboratory studies revealed total white cell count 5.8 x109, mild lymphopaenia 1.0 bil/L, anaemia with Hb 10.2 g/ dL, normal renal function along with a low anion gap and low albumin. Serum protein electrophoresis revealed IgM kappa monoclonal protein with a total IgM level of 82 mg/dL.
Initial chest X-ray demonstrated a right pleural effusion (figure 1). A CT chest was subsequently performed and showed a large right-sided pleural effusion with associated compressive atelectasis and slight mediastinal shift to the left. Additionally, it demonstrated adenopathy in the lower neck and upper thorax, which was increased in size compared with CT scan from 3 years ago. Lymphadenopathy was also noted at the thoracic duct, near the confluence of the left subclavian left internal jugular veins (figure 2).
TreaTmenT
The patient underwent thoracentesis and 1.4 L of milky fluid was removed. Pleural fluid differential showed total white cell count of 13 140/mcL, red blood cell count 4000/mcL, 75% neutrophil count, 22% lymphocytes and monocytes 3%. Analysis of pleural fluid showed elevated triglycerides of 319 mg/dL consistent with chylothorax. Flow cytometry of the pleural fluid showed that 3% of total cells were monotypic B cells, expressing CD19, CD20, CD45 and kappa light chain but were negative for CD5 and CD10. The T cells (36% of total cells) showed a CD4:CD8 ratio of 4.8:1, with normal expression of CD5. Cytology of fluid revealed moderately cellular effusion with abundant small lymphocytes mixed with a few reactive mesothelial cells. Findings were consistent with B-cell lymphoma.
ouTcome and follow-up
Following thoracentesis, she had slight improvement in her shortness of breath. She was also started on a fat-free diet. However, she developed re-accumulation of pleural fluid several days later and required second thoracentesis with pigtail catheter placement. Repeat fluid analysis showed decreasing triglycerides to 94 mg/dL and negative cultures. She was discharged in stable condition; pigtail catheter was removed prior to discharge.
The patient was followed as outpatient by oncology. She underwent repeat bone marrow biopsy 1 month later, which demonstrated hypercellular marrow with 90% infiltrate of small-to-intermediate lymphocytes and plasma cells. Flow cytometry of marrow showed a population of B cells positive for CD19, CD20, CD23 and surface immunoglobulin kappa consistent with extensive infiltration by B-cell lymphoma. She was started on ibrutinib 420 mg every night. Her pleural effusion resolved within 2 months and she did not need any further thoracentesis.
diScuSSion
WM as a cause of chylothorax has previously been only described in seven cases in literature. [17] [18] [19] [20] [21] [22] [23] In the only other case in English literature by Poisson et al, the patient was an 82-year-old man with a known diagnosis of WM and had moderate infiltration of bone marrow with lymphoma. 17 Similar to our case, he presented with dyspnoea and large pleural effusion. CT imaging revealed lymphadenopathy in the left posterior costomediastinal angle associated with a predominantly left-sided effusion. He was treated with rituximab, cyclophosphamide and dexamethasone with resolution of the chylothorax.
The predominant mechanism in malignancy-induced chylothorax is thoracic duct obstruction. Mediastinal lymphadenopathy compresses the lymphatic vessels and prevents drainage of lymph from the lung periphery resulting in extravasation of chyle into the pleural space. 24 However, other mechanisms might be involved. In the aforementioned case, the authors concluded that rather than obstruction of thoracic duct, direct pleural invasion of lymphoplasmacytic cells in pleura causing dilatation and proliferation of the lymph vessels might have played a role, as protein electrophoresis of chylous fluid showed the presence of pleural protein.
In our case, we believe that obstruction of the thoracic duct was the main mechanism of pleural effusion. CT revealed significant lymphadenopathy near the confluence of the thoracic duct and left subclavian left internal jugular vein. However, effusion was mostly right sided as opposed to expected left-sided effusion from presumed damage above T5; therefore, other mechanisms might have played a role.
A unique aspect of our case is that treatment with ibrutinib led to complete resolution of the effusion and symptoms. Ibrutinib is a Bruton's tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of WM. A phase II trial of ibrutinib in 63 patients with symptomatic WM reported an overall response rate of 91% (10 very good partial response, 36 partial response, 11 minor response, none complete). 25 Such immunotherapy agents may allow treatment of WM-related-and perhaps other malignancy-relatedchylothorax without necessitating surgical intervention.
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